İstinye University, MLP Care, Evideep, and GSK Turkey have signed a pioneering collaboration in the field of adult health and chronic diseases. As part of this collaboration, the parties will work together on clinical research, as well as creating and analyzing real-world data.
Turkey's leading universities, İstinye University, MLP Health Services (MLP Care), which is the country's largest private healthcare group with the Medical Park and Liv Hospital brands, global technology and clinical research company Evideep, and GSK, a global biopharmaceutical company with a pioneering position both globally and in Turkey, have launched a scientific collaboration that will contribute to public health and the country's economy.
The protocol, signed with the participation of İstinye University Rector Prof. Dr. Erkan İbiş, MLP Care Strategy and Performance Group Coordinator Dr. Hikmet Çavuş, Evideep Turkey Country Manager Utku Ceylan, and GSK Turkey General Manager Sriram Jambunathan, will involve the creation of ecosystems in hospitals within the MLP Care Group for clinical research, primarily focusing on clinical trials, as well as collecting and analyzing anonymous real-world data. Additionally, data-driven studies related to chronic diseases will be carried out as part of the collaboration.
"We are a university dedicated to research"
İstinye University Rector Prof. Dr. Erkan İbiş expressed his belief that this project will be a strong example of university-industry collaboration, stating: "İstinye University is a university dedicated not only to education but also to research. Despite being only 10 years old, our university is proud to be the youngest foundation university to enter the top 1000 universities in the Times Higher Education World Rankings. The success İstinye University has achieved in such a short time is not only due to the strength of the Medical Park and Liv Hospital brands within the MLP Care Group, but also to the value-added collaborations we have with leading companies in the sector. In this context, we place great importance on this collaboration. We even view it as a lifelong partnership. As part of this project, we will also carry out studies that will support both our university and GSK. We will establish branded course concepts for our students to benefit from. We will also have collaborations in research, including university-industry projects, EU-based international projects, and publications."
"Our agreement is a pioneering and innovative example in Turkey"
MLP Care Strategy and Performance Group Coordinator Dr. Hikmet Çavuş emphasized that the collaboration will bring significant opportunities to Turkey in the field of clinical research, noting that the studies conducted under the supervision of physicians in hospitals will provide patients with access to innovative and effective treatment options and contribute to improving public health by assisting in the management of chronic diseases. Dr. Çavuş said, "We know the importance of working with physicians who are respected in the academic community and keep up with medical developments worldwide. Therefore, as a group, we encourage and support our physicians to carry out academic studies to increase their scientific depth. This is one of our strategic priorities. Through this collaboration, we aim to involve more of our physicians in clinical studies. I believe that under the leadership of our physicians, we will achieve clinical research results that will make our country proud in terms of public health."
"A project that will develop the entire ecosystem"
Evideep Turkey Country Manager Utku Ceylan stated, "The project aims to process real-world anonymous data using advanced technology and create innovative treatments as a result of studies conducted in hospitals. This is very exciting from a patient benefit perspective. Additionally, physicians involved in the project will be able to increase their global publications. It will be a project that develops and grows the ecosystem, encompassing all parties involved in producing and receiving healthcare. We are very happy to be part of this collaboration as Evideep."
"We will continue to make a difference in adult immunization with our innovative health solutions"
GSK Turkey General Manager Sriram Jambunathan commented, "As GSK, we place great importance on technological developments in our sector and have taken significant steps to make Turkey one of the priority countries in terms of data production, real-world data, and clinical trials. In line with our expertise in chronic diseases and adult immunization, we aim to contribute to the development of Turkey's health ecosystem, especially in adult immunization, through projects that are compatible and complementary with the healthcare sector, in collaboration with healthcare providers and professionals. Global research shows that every dollar invested in adult immunization brings an economic return of $19 beyond healthcare costs. We believe that every improvement made in the adult immunization ecosystem will have extremely positive contributions to Turkey’s health economy and ecosystem."
https://www.ohe.org/publications/the-socio-economic-value-of-adult-immunisation-programmes/
